bpc-157 + kpv blend
KPV reduced inflammatory signaling in cells and inflammation in mouse colitis models. BPC-157 plus KPV is sold for gut inflammation and tissue repair, but no controlled human trial has tested the blend for IBS, inflammatory bowel disease, or a damaged gut lining.
BPC-157 + Lys-Pro-Val
- BPC-157 + Lys-Pro-Val
- Gut-mechanism findings are mainly preclinical
What is in the BPC + KPV pairing?
BPC-157 and the tripeptide Lys-Pro-Val are separate ingredients. A capsule and an injectable mixture are different interventions. The ingredient names alone do not establish where either component reaches an effective exposure.
FDA · BPC-157 evidence review
Regulatory safety assessment
FDA · BPC-157 evidence review
The FDA review separates laboratory and animal findings, limited human reports, and marketed combination products. It identifies no demonstrated benefit, established safe formulation, or FDA approval for BPC-157.
Read the original sourceFDA · KPV evidence review
Regulatory safety assessment
FDA · KPV evidence review
The review describes KPV combination marketing and the lack of an adequate human efficacy and safety basis. Proposed gut or tissue-repair uses are not established clinical outcomes for a KPV-containing blend.
Read the original sourceHas this exact combination been tested?
The cited records contain no controlled human outcome study of the BPC-157/KPV combination. The FDA KPV review describes proposed combinations without establishing efficacy.
Exact combination · no controlled human study
Literature record set
PubMed and cited primary records.
The cited records contain no controlled human outcome study of the BPC-157/KPV combination. The FDA KPV review describes proposed combinations without establishing efficacy.
What does the KPV gut research show?
KPV reduced inflammatory signaling in cells and inflammation in mouse colitis models. The cited work did not test this blend in people with IBS or inflammatory bowel disease.
What is PepT1, and why does it matter?
PepT1 is a transporter investigated in the KPV work. The experiment helps explain how KPV entered cells, but it did not measure absorption, tissue concentration, or symptom improvement from a marketed oral blend.
KPV · cells and mouse colitis
Cell and animal study
Dalmasso G et al. Gastroenterology, 2008. PMID 18061177.
KPV affected inflammatory signaling in cultured intestinal and immune cells and reduced inflammation in mouse colitis models. The study did not test BPC-157/KPV or KLOW in people.
Read the original sourceWhat supports the blend's repair and anti-inflammatory rationale?
The proposed rationale pairs BPC-157 tissue-repair findings with KPV anti-inflammatory findings. No cited clinical study measured the combination, compared it with either ingredient alone, or showed that it prevents ongoing tissue damage.
FDA · BPC-157 evidence review
Regulatory safety assessment
FDA · BPC-157 evidence review
The FDA review separates laboratory and animal findings, limited human reports, and marketed combination products. It identifies no demonstrated benefit, established safe formulation, or FDA approval for BPC-157.
Read the original sourceFDA · KPV evidence review
Regulatory safety assessment
FDA · KPV evidence review
The review describes KPV combination marketing and the lack of an adequate human efficacy and safety basis. Proposed gut or tissue-repair uses are not established clinical outcomes for a KPV-containing blend.
Read the original sourceWhat are the side effects and main unknowns?
The blend has no measured adverse-event profile. FDA reports no human exposure data for KPV-containing drug products and describes limited route-specific safety information for BPC-157. Human tolerability remains unknown.
FDA · ingredient safety concerns
Regulatory safety assessment
FDA · ingredient safety concerns
FDA describes limited human safety information for BPC-157 and concerns about impurities, product characterization and immune reactions. For KPV drug products, the agency reports no human exposure data.
Read the original sourceIs oral use supported better than injection?
The cited evidence does not establish an effective oral or injected regimen for this exact pairing. Mouse-colitis findings, a transport experiment and an injection report for another condition cannot be combined into a human treatment schedule.
Can it replace treatment for inflammatory bowel disease?
The cited records contain no clinical comparison with established IBD treatment and do not show that substituting this blend maintains disease control. The proposed mechanism does not answer that treatment question.
KPV · cells and mouse colitis
Cell and animal study
Dalmasso G et al. Gastroenterology, 2008. PMID 18061177.
KPV affected inflammatory signaling in cultured intestinal and immune cells and reduced inflammation in mouse colitis models. The study did not test BPC-157/KPV or KLOW in people.
Read the original sourceExact combination · no controlled human study
Literature record set
PubMed and cited primary records.
The cited records contain no controlled human outcome study of the BPC-157/KPV combination. The FDA KPV review describes proposed combinations without establishing efficacy.
Studies and sources
FDA · BPC-157 evidence review
Regulatory safety assessment
FDA · BPC-157 evidence review
The FDA review separates laboratory and animal findings, limited human reports, and marketed combination products. It identifies no demonstrated benefit, established safe formulation, or FDA approval for BPC-157.
Read the original sourceFDA · KPV evidence review
Regulatory safety assessment
FDA · KPV evidence review
The review describes KPV combination marketing and the lack of an adequate human efficacy and safety basis. Proposed gut or tissue-repair uses are not established clinical outcomes for a KPV-containing blend.
Read the original sourceKPV · cells and mouse colitis
Cell and animal study
Dalmasso G et al. Gastroenterology, 2008. PMID 18061177.
KPV affected inflammatory signaling in cultured intestinal and immune cells and reduced inflammation in mouse colitis models. The study did not test BPC-157/KPV or KLOW in people.
Read the original sourceFDA · ingredient safety concerns
Regulatory safety assessment
FDA · ingredient safety concerns
FDA describes limited human safety information for BPC-157 and concerns about impurities, product characterization and immune reactions. For KPV drug products, the agency reports no human exposure data.
Read the original sourceExact combination · no controlled human study
Literature record set
PubMed and cited primary records.
The cited records contain no controlled human outcome study of the BPC-157/KPV combination. The FDA KPV review describes proposed combinations without establishing efficacy.
Why is bpc-157 + kpv blend in A tier?
C reflects component-level preclinical evidence, including KPV findings in cultured cells and mouse colitis models. The marketed blend has no measured human treatment effect in the cited sources.